CPC A61J 1/1468 (2015.05) [A61J 1/00 (2013.01); A61J 1/065 (2013.01); A61K 31/403 (2013.01); A61K 38/17 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 38/28 (2013.01); A61K 39/3955 (2013.01); C03C 3/087 (2013.01); C03C 3/091 (2013.01); C03C 4/20 (2013.01); C03C 21/002 (2013.01); C07K 16/241 (2013.01); Y02A 50/30 (2018.01); Y10T 428/131 (2015.01)] | 49 Claims |
1. A delamination resistant pharmaceutical container comprising a pharmaceutical composition stored within the container, wherein the pharmaceutical container comprises a glass composition comprising:
SiO2 in a concentration greater than 74 mol. %;
ZrO2 in a concentration less than 1 mol. %;
alkaline earth oxide comprising MgO and CaO, wherein CaO is present in an amount greater than or equal to 0.1 mol. % and less than or equal to 1.0 mol. % relative to the glass composition, and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5; and
Y mol. % alkali oxide, wherein the alkali oxide comprises Na2O in an amount greater than 8 mol. %, wherein the glass composition is free of boron and compounds of boron, and
wherein the pharmaceutical composition comprises one of insulin or an analog thereof, insulin lispro, a nucleoside analog, an analog of deoxycytidine, or gemcitabine.
|